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MitochondrionIron is a crucial transition metal for virtually all life. Two major destinations of iron within mammalian cells are
the cytosolic iron-storage protein, ferritin, and mitochondria. In mitochondria, iron is utilized in critical anabolic
pathways, including: iron-storage inmitochondrial ferritin, heme synthesis, and iron–sulfur cluster (ISC) biogen-
esis. Although the pathways involved in ISC synthesis in the mitochondria and cytosol have begun to be charac-
terized, many crucial details remain unknown. In this review, we discuss major aspects of the journey of iron
from its initial cellular uptake, its modes of trafﬁcking within cells, to an overview of its downstream utilization
in the cytoplasm and within mitochondria. The understanding of mitochondrial iron processing and its commu-
nication with other organelles/subcellular locations, such as the cytosol, has been elucidated by the analysis of
certain diseases e.g., Friedreich's ataxia. Increased knowledge of the molecules and their mechanisms of action
in iron processing pathways (e.g., ISC biogenesis)will shape the investigation of ironmetabolism inhumanhealth
and disease.
© 2015 Elsevier B.V. All rights reserved.1. Overview of mammalian iron metabolism
Iron is vital for cellular survival, as demonstrated by cell death
following excessive iron depletion [1–3]. Adult humans contain ~3–
5 g of iron, up to 80% of which is found in erythrocyte hemoglobin,
while a further ~20% is stored within macrophages and hepatocytes
[2,4]. Cellular iron storage typically occurs within protein nanocages
created by ferritin [5]. The remainder of the iron is present in
other heme-containing proteins (e.g., cytochromes), iron–sulfur
cluster (ISC)-containing proteins (e.g., succinate dehydrogenase)oleuvulinate synthase; CIA, cyto-
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ne),[6,7] and non-heme/non-ISC iron-containing proteins (e.g., iron-
and 2-oxoglutarate-dependent dioxygenases) [8,9].
Improperly sequestered iron catalyzes toxic reactive oxygen species
(ROS) through Fenton andHaber-Weiss-type reactions [2]. As toomuch
or too little iron is detrimental, iron homeostasis is tightly controlled
through the regulation of its import, storage and efﬂux [2,10–12].
1.1. Two major routes of cellular iron uptake
Non-heme iron is transported into cells by two mechanisms: trans-
ferrin (Tf)-bound iron uptake and non-Tf-bound iron (NTBI) uptake
(Fig. 1). Under physiological conditions, almost all iron in the circulation
is bound to Tf [2,11]. However, in diseases resulting in iron overload, Tf
becomes saturatedwith iron,with excess plasma iron occurring as NTBI
[2]. The exact uptake route(s) for NTBI remains unclear, but appears to
involve one or more cell surface ferrireductases (e.g., duodenal cyto-
chrome b, DCYTB [13]) or the release of cellular reductants, such as
ascorbate [14–17] (Fig. 1). These enzymes reduce ferric NTBI to its
ferrous state that can then be imported by transporters such as the
transmembrane protein, divalent metal transporter 1 (DMT1) [18], or
the ZRT/IRT-like proteins (ZIPs), ZIP14 or ZIP8 [19].
Under physiological circumstances, the major iron uptake route
utilized by most cells involves Tf-bound iron, which is internalized by
receptor-mediated endocytosis after binding to transferrin receptor 1
(TfR1) [11,12] (Fig. 1). Ferric iron is released from Tf within the
endosome after its acidiﬁcation and is then reduced by an endosomal
ferrireductase (e.g., six transmembrane epithelial antigen of the pros-
tate 3 [STEAP3] [20]) [12], or by an novel mechanism involving cellular
Fig. 1. Twomajor cell iron (Fe) uptake pathways, namely transferrin (Tf)-bound Fe uptake
and non-Tf-bound Fe (NTBI) uptake. Under physiological conditions, most Fe is bound to
Tf which binds to the transferrin receptor 1 (TfR1) on the cell surface that is then involved
in receptor-mediated endocytosis with the Fe being released from Tf by a decrease in
endosomal pH and reduction by an endosomal reductase [e.g., six transmembrane epithe-
lial antigen of the prostate 3 (STEAP3)] or, potentially, by ascorbate. The Fe(II) is then
transported across the endosomal membrane by divalent metal transporter 1 (DMT1)
where it then becomes part of the poorly characterized labile iron pool (LIP) in the cytosol.
Iron in the LIP acts as an intermediate and can be utilized for storage in the iron storage
protein, ferritin, or used for synthesis of heme and iron-sulfur clusters in themitochondri-
on or cytosol. Iron can also be exported from the cell by ferroportin 1 (FPN1). In conditions
of iron overload, NTBI exists in the blood, and may be taken up by processes that include
cell surface reduction by ferrireductases such as duodenal cytochrome b (DCYTB), or by
efﬂuxed reductants, such as ascorbate. Intracellular ascorbate can also supply electrons
for DCYTB-dependent ferrireduction. Such enzymes reduce ferric NTBI to its ferrous
state, which can be imported from the plasma membrane by transporters such as DMT1.
1131D.J.R. Lane et al. / Biochimica et Biophysica Acta 1853 (2015) 1130–1144ascorbate [14,21,22]. Similarly to NTBI uptake, this ferrireduction is
followed by transport of the resulting ferrous iron across the endosomal
membrane by DMT1 [18] or ZIP14 [19]. This nascent cytosolic iron then
becomes part of a poorly characterized chelatable or labile iron pool
(LIP) and can be utilized for metabolism, stored in ferritin or released
back to the extracellular space [11,12] (Fig. 1).
1.2. Cytosolic iron trafﬁcking
Tf-bound iron and NTBI entering the transitory LIP is either:
(i) stored in ferritin; (ii) utilized by downstream metabolic pathways
(e.g., imported into mitochondria for usage in ISC and heme synthesis,
and/or incorporated in cytoplasmic iron-requiring proteins); or (iii) re-
leased from the cell by the ferrous iron exporter, ferroportin 1 (FPN1)
(Fig. 1).
In non-erythroid cells, the majority (i.e., 70–80%) of this newly
imported iron is incorporated into ferritin [5]. Ferritin is a multimeric
protein composed of 24 subunits that forms a hollow sphere capable
of storing ~4,500 iron atoms as a mineralized ferric, phosphate and
hydroxide core [5,23,24]. In mammals, there are two ferritin subunits:
H-ferritin (heavy subunit, encoded by FTH1) and L-ferritin (light sub-
unit, encoded by FTL), which hetero-polymerize to form different
isoferritins with tissue speciﬁc distributions [5,23,24]. Iron(II) entering
ferritin is oxidized to iron(III) by the ferroxidase activity of H-ferritin
in an oxygen-dependent manner [5,23,24]. Subsequently, iron(III) is
transported to the protein cavity, where core formation commencesat carboxyl groups on glutamates of L-ferritin,which is devoid of ferrox-
idase activity [5,23,24]. This enclosure and sequestration of iron as ferri-
hydrite is vital, as it prevents toxic redox reactions from occurring [5,23,
24].
Ferritin typically releases iron in a controlled manner under
in vivo conditions by targeted autolysosomal proteolysis, although
proteasomal degradation of the protein can occur under speciﬁc con-
ditions [5,25]. The targeting of ferritin for autophagic turnover (i.e.,
ferritinophagy) has recently been shown to involve nuclear receptor
coactivator 4 (NCOA4), which binds to ATG8 proteins on forming
autophagosomes and recruits ferritin as a cargo molecule [26]. Consid-
ering that autophagocytosed macromolecules and organelles, such as
ferritin and mitochondria, contain relatively high levels of iron, active
lysosomal compartments are rich in this metal [27]. Interestingly, stud-
ies have suggested the possibility that the lysosome may also be
involved in iron storage, due to the expression of various membrane
metal transport proteins on lysosome-like organelles [28].
1.3. Intracellular iron transport: low-molecular weight (Mr) iron pool or
directed protein–protein transfer?
While the nature of the LIP may consist of low-Mr iron complexes,
accumulating evidence supports the hypothesis that iron is typically
transported in a direct manner via a complex of interacting proteins,
in which the binding of iron to each component acts as an intermediate
that minimizes cytotoxic redox chemistry within the oxygen-rich envi-
ronment of the cell [3,29,30]. Indeed, a putative protein-containing
high-Mr intermediate that appeared to donate its iron to ferritin has
been observed after incubation of K562 cells with Tf-59Fe [30].
More recently, studies have demonstrated a chaperone role for
human poly (rC)-binding proteins 1-4 (PCBPs 1-4) in iron transport to
ferritin and other non-heme iron requiring proteins [9,31–33]. The
PCBPs are members of the heterogenous nuclear ribonucleoprotein
family, and is comprised of PCBPs 1-4. These proteins are classical
RNA/DNA-binding proteins involved in diverse processes such as splic-
ing, transcript stabilization and translational regulation [34]. In 2008,
PCBP1was identiﬁed as being crucially involved in ferritin ironmineral-
ization through functional screening of a human liver cDNA library in
yeast [35]. In this assay, it was identiﬁed that PCBP1 and human ferritin
coexpression in naturally ferritin deﬁcient yeast cells caused an iron de-
ﬁciency response, indicating PCBP1-dependent ferritin iron loading
[35]. Further biochemical, biophysical and genetics experiments have
provided support for the role of PCBP1 as an iron chaperone for ferritin
[31,35].
As novel iron chaperones, the PCBPs 1-4 can assist in the delivery of
iron to the cytosolic iron storage protein, ferritin, in mammalian cells
[31,35]. However, while PCBPs 1-3 can directly bind ferritin, PCBP4 ap-
pears to act indirectly, perhaps as an intracellular iron buffer for the
other PCBPs [8,31]. Indeed, iron-loaded PCBP1 is able to bind to ferritin
in vivo and in vitro in multiple molar equivalents with low micromolar
afﬁnity, as was determined from isothermal titration calorimetric stud-
ies [31,36]. This binding afﬁnity of iron-PCBP1 for ferritin ismuchhigher
than the binding afﬁnity of iron(II) for ferritin or the afﬁnity of apo-
PBCP1 for ferritin [31,35]. The binding of iron-loaded PCBP1/2 to ferritin
may act to increase the efﬁciency of iron loading into nascent ferritin
polymers [31].
PCBP 1, and probably PCBP2 [8], appears to be able bind Fe(II) in a six
coordinate oxygen/nitrogen ligand environment [36]. PCBP1 can bind a
total of three iron atoms, in which the ﬁrst iron atom has a dissociation
constant (Kd) of 0.9 ± 0.1 μM and a mean Kd of 5.8 ± 0.3 μM for the re-
maining two iron atoms [9,32,35]. Iron-loaded PCBP1 exhibits a stoichi-
ometry of binding of approximately nine iron-PCBP1 units per ferritin
oligomer [31]. Given that the number of putative iron delivery channels
is eight per ferritin polymer of 24 subunits, this stoichiometry of PCBP1
binding to ferritin supports amodel of iron delivery via direct binding of
iron-PCBP1 molecules near the iron delivery channels formed by the
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ritin in a lower stoichiometric ratio of 4:1 iron-PCBP2:ferritin [31].
The functions of PCBPs 1 and 2 appear to be non-redundant in the
delivery of iron to ferritin [8]. PCBP1 and PCPB2 can self-associate as
well as form complexes with other PCBPs and other RNA-binding pro-
teins [9,32]. Although PCBP1 and PCBP2 can be detected as a complex
in human cells, their association appears to be relatively unstable [31,
37]. Importantly, both PCBP1 and PCBP2 are essential for the formation
of a stable hetero-oligomeric complex with ferritin [31]. This has been
demonstrated in studies in which the interaction between ferritin and
PCBP1 or PCBP2 is reduced upon PCBP2 or PCBP1 depletion, respectively
[8,31,37]. That is, depletion of either one of the PCBPs reduces the bind-
ing of the other paralog to ferritin, suggesting that the hetero-oligomer
of PCBP1 and PCBP2 can more stably bind ferritin compared to either
the homo-oligomer or monomeric PCBPs [31].
The requirement for both PCBPs in binding to ferritin and delivery of
iron to this protein may relate to the recent ﬁnding that PCBP2 is a
DMT1-binding partner that regulates iron inﬂux from Tf-iron across
the endosomal membrane to the cytosol [33]. As PCBP2 binds iron and
associates with ferritin to deliver iron [8,31], this may be the ﬁrst direct
evidence of an iron-transport complex. Further studies are required to
assess this possibility.
PCBPs 1 and 2 also appear to mediate iron acquisition by several
members of a class of iron- and 2-oxoglutarate (2-OG)-dependent
dioxygenases, which form a large family of non-heme iron enzymesFig. 2. Cellular iron homeostasis. There are two major regulatory mechanisms mediated by: (A
(HIF1 and 2). (A) The IRP/iron responsive element (IRE) system regulates the translation of pro
iron uptake (TfR1, DMT1, MRCKα), the mitochondrial citric acid cycle (ACO2), mitochondrial
conditions of low iron, the IRPs are in their IRE-binding forms. Under conditions of high iron, t
which converts it into a cytosolic aconitase incapable of binding IREs, while IRP2 is targeted
iron is low, the binding of IRP1 or IRP2 to IREs in the 5′-UTR of select mRNAs inhibits translatio
against nuclease-mediated degradation, leading to increased translation (↑).When cellular iron
is increased (↑), whilemRNAs possessing 3′ IREs are degraded faster, leading to decreased prote
by the hypoxia-inducible factor (HIF) system. Under conditions of high iron, O2 and ascorbate,
ylase domain proteins (PHDs 1–3). Prolyl hydroxylation targets HIF1/2α proteins for ubiquitin
iron, O2 and ascorbate concentrations, HIF1/2α proteins are stabilized and form hetero-dimers
possessing hypoxia response elements (HREs). Additionally, high iron,O2 and ascorbate levels in
1 (FIH1), which inhibits HIF transcriptional activity.
Modiﬁed from (Lawen and Lane) [2].that depend on the insertion of a single iron atom into their active site
[8]. The enzymes identiﬁed as putative recipients for PCBP-mediated
iron delivery are themono-nuclear iron-center hypoxia inducible factor
1α (HIF1α) prolyl and asparaginyl hydroxylases, prolyl hydroxylase 2
and factor inhibiting HIF, respectively, as well as the dinuclear iron
center of deoxyhypusine hydroxylase [9,31,32]. For a recent review
see Philpott and Ryu [8].1.4. Control of cellular iron homeostasis
Cellular iron homeostasis is tightly regulated by a post-
transcriptionalmechanism thatmodulates the synthesis of key ironme-
tabolism proteins involved in iron uptake, storage and release [1,10].
Speciﬁcally, the iron regulatory protein (IRP)-iron responsive element
(IRE) system is responsible for this post-transcriptional regulation,
and allows for rapid alterations in the synthesis of key iron metabolism
proteins in response to intracellular iron levels [1,10,38]. This system
depends on the mRNA-binding proteins, IRPs 1 and 2, which post-
transcriptionally control the expression of mRNAs possessing IREs [1,
10,38] (Fig. 2A). IRPs bind to IREs in the 5′- or 3′ untranslated regions
(UTRs) of key mRNAs involved in iron metabolism with high afﬁnity
in iron-depleted cells, either suppressing the translation of the mRNA
(i.e., mRNAs in which the IRE is located in the 5′ UTR; e.g., FTH1, FTL,
FPN1 etc.), or by enhancing mRNA stability against nuclease attack) iron regulatory proteins 1 and 2 (IRPs 1 and 2); and (B) hypoxia inducible factor 1 and 2
teins involved in iron storage [H-ferritin (FTH1) and L-ferritin (FTL)], iron export (FPN1),
heme synthesis (ALAS2), oxygen sensing (HIF2α) and cell cycle control (CDC14A). Under
he IRE-binding activity of the IRPs is decreased. IRP1 acquires an iron-sulfur cluster (ISC),
for degradation by the proteasome by the FBXL5 E3 ligase complex. When intracellular
n (↓) of themRNA, while the binding of IRPs to IREs in the 3′-UTRs protects the transcripts
is high, there is decreased IRP–IRE binding, and the translation ofmRNAs possessing 5′ IREs
in translation (↓). (B) Cellular ironmetabolism is also regulated at the transcriptional level
HIF1α and HIF2α are hydroxylated at speciﬁc proline residues by a class of prolyl hydrox-
ation by the E3 ubiquitin ligase, von Hippel Lindau protein (VHL). Under conditions of low
with HIF1β that translocate to the nucleus and activate the transcription of speciﬁc genes
creasehydroxylation activity of the asparaginyl hydroxylase knownas factor inhibitingHIF
Fig. 3.Mitochondrial iron import pathways. There are three potential iron uptake path-
ways that provide the metal for transport across the outer mitochondrial membrane via
an unknown transporter (designated “?”), and into the mitochondrion, all of which may
involve mitoferrin isoforms (MFRN) in the inner mitochondrial membrane. These are:
(1) the hypothesized endosomal “kiss-and-run” mechanism, which involves the direct
interaction of the endosome with the mitochondrion; (2) direct iron uptake by the mito-
chondrion from the LIP (potentially chelator-accessible iron); and (3) the donation of iron
to the mitochondrion by protein–protein interactions that are potentially chelator-
inaccessible, including speciﬁc chaperone molecules that transport and deliver iron to
the mitochondrion.
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etc.) [10,12].
Under conditions of increased cellular iron,which can be potentiated
by endogenous reductants such as ascorbate [14], IRP1 loses its IRE-
binding activity by acquiring an ISC (4Fe–4S cluster) [38]. The acquisi-
tion of this 4Fe–4S cluster converts IRP1 into a cytosolic aconitase
(Fig. 2A). In the case of IRP2, the iron-dependent, proteasomal degrada-
tion is the major regulatory mechanism [39]. On the other hand, IRP2,
which is unable to acquire an ISC in response to increased cellular
iron, is post-translationally regulated by proteasomal degradation [39]
(Fig. 2A).
The major mechanism by which iron regulates proteasomal degra-
dation of IRP2 is by targeting of IRP2 to a subunit of the SKP1-Cullin-
1-F-box E3 ubiquitin ligase complex, namely F-box and Leucine-rich
Repeat Protein 5 (FBXL5), which is post-translationally regulated by
iron and oxygen [40,41]. FBXL5 contains a hemerythrin-like domain
that is capable of binding iron, leading to stabilization of the protein,
preventing proteasomal degradation [40,41]. This leads to a consequent
loss of IRP2 due to increased ubiquitination and subsequent degradation
of IRP2 [40,41] (Fig. 2A).
Regulation of cellular iron homeostasis is also controlled at the level
of the transcription of ironmetabolismgenes. Amajor regulator of these
changes in transcription is the HIF system, which includes the oxygen-
and iron-regulated proteins, HIF1α and HIF2α [42] (Fig. 2B). Low oxy-
gen tensions (i.e., hypoxia), as well as low intracellular iron concentra-
tions, activate HIF1 and HIF2-regulated transcription by the increased
formation of heterodimers of HIF1α or HIF2α with the constitutively
expressed HIF1β subunit [42]. HIF1α is ubiquitously expressed, while
HIF2α has a more restricted tissue distribution [12,43a]. The HIFα/β
heterodimers form transcription factors that regulate a range of genes
encoding proteins important for cellular oxygen homeostasis and the
response to hypoxia [42] (Fig. 2B).
Both HIF1α and HIF2α are post-translationally regulated through
protein degradation or inhibition of their transcriptional activity in an
oxygen- and iron-dependent manner [42] (Fig. 2B). This occurs by a
speciﬁc class of 2-oxoglutarate-dependent dioxygenases: the prolyl-4-
hydroxylase domain-containing iron-dependent prolyl hydroxylases
(PHDs) 1-3, which regulate HIF1/2α degradation, and the asparaginyl
hydroxylase, factor inhibiting HIF1 (FIH1), which inhibits HIF1α-
complex transcriptional activity [43a]. Under conditions of iron reple-
tion, these hydroxylases are fully active at the oxygen tensions found
under typical cell-culture conditions (i.e., 21%) [43a]. PHDs hydroxylate
HIF1/2α proteins at speciﬁc proline residues, leading to proteasomal
degradation, while FIH1 hydroxylates a conserved asparagine residue,
resulting in inactivation of transcriptional activity [43a] (Fig. 2B). Impor-
tantly, it is the strict dependence of these hydroxylases on iron that
allows cellular iron to modulate HIF-regulated gene expression [43a].
The hydroxylated α-subunits of HIF are targeted for ubiquitination by
the elongin B/elongin C/cullin 2/von Hippel–Lindau (VHL) E3 ubquitin
ligase (also known as CRL-2) subunit, VHL, which directs the proteins
to be degraded by the proteasome (Fig. 2B) [42]. Importantly, HIF2α
contains an IRE in its 5'-UTR, and is regulated by IRP1. The IRP1-HIF2
axis is an important iron- and hypoxia-dependent regulator of key
genes that contribute to iron absorption from the gut (i.e., DCYTB,
DMT1 and FPN1) and to erythropoiesis (i.e., EPO). For a recent review,
see Shah et al. [43b].2. Mitochondrial iron metabolism
Mitochondria play a vital role in cellular iron metabolism [3,44].
These organelles are the sole site of heme synthesis (Fig. 3) and the
major site for ISC biogenesis [7,44,45]. As many of the proteins depend-
ing on these iron-containing groups play vital roles in cellular metabo-
lism, the dysregulation of mitochondrial iron metabolism often leads
to severe diseases [7,46,47].2.1. Mitochondrial iron import
While the pathways involved in heme and ISCs synthesis are largely
known (see below), only more recently have some of the molecular
players involved in mitochondrial iron transport been identiﬁed. Iron
may be imported from the cytosol across the outer mitochondrial
membrane (OMM) by one or more of the following mechanisms
(Fig. 3): (i) by a putative endosomal “kiss-and-run” or direct protein–
protein transfer mechanism, at least in hemoglobin-producing ery-
throid precursors, in which Tf-containing endosomes make a transient
contact with the OMM [29]; (ii) direct uptake of iron(II) from the cyto-
sol, driven by themitochondrialmembrane potential (ΔΨm) [2]; and/or
(iii) uptake of a “chelator-inaccessible” iron pool from the cytosol,
which may involve directed transfer by protein–protein contacts [2].
In order for iron to enter the mitochondrial matrix to be processed
by the heme and ISC synthetic pathways, iron must traverse the OMM
and inner mitochondrial membrane (IMM). The passage of iron across
the OMM, which has high metabolite-permeability relative to the
IMM, is due largely to the presence of voltage-dependent anion chan-
nels (VDACs), remains ill-deﬁned. Indeed, VDACs are the most singly
abundant proteins in the OMM, and are responsible for the shuttling
of almost all energy-related metabolites, including pyruvate, ATP, etc.
between the cytosol and themitochondria [48]. VDACs also have cation-
ic conductance andmay be responsible for allowing the trans-OMMﬂux
of divalent cations such as Ca2+ and Mg2+ [48]. An untested possibility
is that VDACsmay facilitate the passage of ferrous iron across the OMM.
Alternatively, a recent study suggested that mitochondrial isoforms of
DMT1 may be involved [49a]. As PCBP2 can bind to DMT1 to facilitate
iron efﬂux from the endosome [33], PCBP2 may similarly promote
iron inﬂux intomitochondria throughDMT1. Further studies are needed
to test these hypotheses.
In contrast, the iron import pathway across the IMM is more com-
prehensively characterized. In budding yeast, two homologous, high af-
ﬁnity iron transporters, Mrs3 and Mrs4, are involved in mitochondrial
iron uptake across the IMM [49b,c]. Orthologs of these proteins,
known as mitoferrins (MRFNs), exist in all eukaryotes. In mammalian
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by the action of one of two MFRN isoforms: MFRN1 or MFRN2 [50,51].
The levels of MFRNs control mitochondrial iron levels, and this regula-
tion occurs at the post-translational level due to alterations in protein
half-life [50]. In the mitochondria of differentiating erythroid cells,
MFRN1 (also knownas SLC25A37) accumulates due to anextended pro-
tein half-life relative to MFRN2 [50], and is responsible for iron import
across the IMM in these red blood cell precursors [51]. As might be ex-
pected, the loss of this protein leads to profound anemia and disruptions
in ISC biogenesis [51]. On the other hand, MFRN2 (also known as
SLC25A28) is ubiquitously expressed in different tissues, and, unlike
MFRN1, its expression does not increase during erythroid differentia-
tion [50,51].
Although the precise biochemistry of MFRN1-mediated iron import
by mitochondria remains unknown, MFRN1 interacts with the IMM
ATP-binding cassette (ABC) transporter 10, which is highly expressed in
erythroidmitochondria, and increases MFRN1 stability andmitochondri-
al iron import [52]. Since a complex consisting of MFRN1, ABCB10 and
ferrochelatase has since been discovered [53], this association may pro-
mote efﬁcient heme synthesis during erythroid development by stabiliz-
ing MFRN1 and funneling iron directly to ferrochelatase, the enzyme
which inserts iron into protoporphyrin IX (PPIX) to form heme [54].
Interestingly, the identity of the transported substrate of ABCB10 remains
unknown, and recent evidence suggests that ABCB10 plays a role in
protection fromoxidative stress duringnormal erythropoiesis and cardiac
recovery [55].Moreover, a very recent study has determined that ABCB10
is critical for heme synthesis, and that Abcb10-knockout mice demon-
strate anemia with PPIX accumulation [56]. Taken together, these data
suggest the role of ABCB10 in erythropoiesis may be to increase MFRN1
stability and complexation with ferrochelatase in order to direct the
large iron inﬂux from Tf into the heme synthesis pathway.
Interestingly, recent studies using Ru360, a speciﬁc inhibitor of the
mitochondrial calcium uniporter (MCU), also suggests the involvement
of the MCU in mitochondrial uptake of Fe(II), possibility via an interac-
tion with the ubiquitously expressed MFRN2 [57,58]. Indeed, blockade
of MCU with Ru360 attenuated mitochondrial dysfunction caused by
iron overload [58]. However, the speciﬁc mechanisms involved in this
process require further elucidation.Fig. 4. There are three major mitochondrial iron metabolic pathways in mitochondria.
Cytoplasmic iron is delivered to the mitochondrion by three possible mechanisms (see
Fig. 4)with transport occurring across the outermitochondrialmembrane (see text for de-
tails). The iron is then transported across the inner mitochondrial membrane via
mitoferrin-1 or -2 (MFRN) and then utilized for: (1) ISC biogenesis; (2) iron storage inmi-
tochondrial ferritin (FTMT); and/or (3) heme synthesis.Once imported by the mitochondrion, there are essentially
three major metabolic pathways for iron: (i) mitochondrial iron stor-
age; (ii) heme synthesis; and (iii) ISC biogenesis (Fig. 4). We provide a
brief overview of the former two pathways (see below), while the
remainder of this review will focus on some recent advances and
controversies in ISC biogenesis and delivery.
2.2. Mitochondrial iron storage
Some mammalian tissues express a mitochondrial-speciﬁc ferritin
(FTMT) that has a high level of sequence identity with H-ferritin.
FTMT stores iron within a homopolymer and demonstrates distinct
iron oxidation and hydrolysis chemistry to H-ferritin [5]. Interestingly,
the highest expression of FTMT is observed in the testis (spermatozoa),
while it appears to be completely absent from typical iron-storage
tissues such as liver and spleen [59]. High levels of FTMT are also
expressed in sideroblasts (i.e., erythroblasts with iron granules) of pa-
tients affected by sideroblastic anemia [59,60a].
2.3. Heme synthesis
Weonly provide a very brief overview of the heme synthesis pathway
here, and direct readers to a recent and comprehensive review on the
topic [60b]. Heme synthesis involves the sequential catalytic activity of
eight enzymes and is dependent on the mitochondrion [54]. Four of the
intermediate enzymatic steps arewithin the cytosol [54]. The biosynthet-
ic pathway spans all mitochondrial compartments, as well as the cyto-
plasm. The ﬁrst enzyme in the pathway is δ-aminoleuvulinate synthase
(ALAS), which catalyzes the condensation of glycine and succinyl-CoA
to form δ-aminolevulinic acid [54]. Two variants of ALAS exist: ALAS2 is
expressed speciﬁcally in erythroid cells, while ALAS1 is expressed in
other cell-types. Unlike ALAS1, the ALAS2mRNA possesses an IRE in its
5′-UTR, and is subject to regulation via the IRP–IRE system (Fig. 2A). It is
due to this difference that in erythroid cells expressing ALAS2, the rate
of heme synthesis may be governed by cytosolic iron availability [54].
Interestingly, MFRNs appear capable of regulating the heme synthe-
sis pathway via the IRP–IRE system. Indeed, a recent report determined
the mechanism behind the lack of porphyria (i.e., an accumulation of
PPIX) in animals lacking MFRN1 [61]. Due to the loss of MFRN1-
dependent mitochondrial iron import, such mutant animals are unable
to synthesize appropriate heme levels during erythroid differentiation
[61]. The mechanism appears to involve an increase in the IRE-binding
form of IRP1 (Fig. 2A), presumably resulting from impaired and iron-
limited ISC biogenesis, that leads to attenuated translation of ALAS2
mRNA (which contains an IRE in its 5′-UTR), decreased ALAS2 protein
synthesis and decreased production of protoporphyrin [61].
The ﬁnal enzyme in the heme synthesis pathway is ferrochelatase,
which inserts iron(II) into the heme precursor, PPIX, to form heme
[54]. Since mammalian ferrochelatase is an ISC-containing enzyme,
any disruption in ISC synthesis may deregulate heme synthesis, as
shown in disease models [62a].
3. Iron–sulfur cluster biogenesis: an overview
3.1. Basic ISC biochemistry and function
ISCs are ancient biochemical structures that are composed of non-
heme iron and inorganic sulﬁde [7]. Although a range of conﬁgurations
exist, ISCs are mostly found in the cubane form (i.e., [4Fe-4S]). These
prosthetic groups are ligated to cysteine residues of proteins and are
necessary for a wide variety of protein functions including: (i) electron
transfers, which are almost all mono-electronic (e.g., as occurs in the
ISC-containing complexes I-III of the respiratory chain); (ii) forming
substrate-binding sites and promoting enzymatic catalysis (e.g., cytosolic
and mitochondrial aconitases); and/or (iii) metabolic sensors (e.g., IRP1/
cytosolic aconitase and the regulation of cellular iron metabolism) [1,7].
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an excellent detailed review, see Lill [6], and for a recent bacteria-specif-
ic review, see Blanc et al. [62b]). The remainder of this review will con-
centrate on themammalian systems, with reference to other organisms
where necessary.Mammalian ISC biogenesis occurs in two different, but
connected systems corresponding to different cellular compartments:
the “ISC” assembly apparatus inmitochondria (the focus of this section)
and the cytosolic ISC biogenesis (CIA) system (overviewed below). Ge-
netic disruptions affecting key proteins involved in ISC cluster
biogenesis are recognized as being involved in the development of
an increasing number of human diseases [7]. In the case ofmitochondri-
al ISC biogenesis, such diseases include Friedreich's ataxia (FRDA), ISC
assembly enzyme (ISCU) myopathy, a rare sideroblastic-like microcytic
anemia, hereditarymyopathywith lactic acidosis, X-linked sideroblastic
anemia with cerebellar ataxia and an encephalomyopathy caused by a
deﬁciency in ISC-dependent complex I activity in the IMM respiratory
chain [7,46,47].
3.2. The core mitochondrial ISC biogenesis pathway
Certain apo-proteins (e.g., some ferredoxins) can acquire their ISCs
following simple addition of S2- and Fe2+/3+ to solution in vitro [63].
While this led to the long-held belief that ISCs could be generated and
incorporated into their apo-proteins spontaneously, this view was not
compatiblewith the known toxicities of free iron and sulfur in biological
systems [63]. It is now known that both iron and sulfur are coordinately
delivered in a minimally toxic form to apo-proteins by carrier proteins,
chaperones and scaffolds [7,46,64].
The process of ISC biogenesis, in general, can be envisaged as occur-
ring in two key phases: (1) the transient synthesis of the ISC on a scaf-
fold assembly protein and (2) the transfer of this de novo ISC to target
apo-proteins [65] (in the case of mitochondrial ISC biogenesis, see
Fig. 5).
In humans, the core ISC assembly machinery includes the dimeric
NFS1 cysteine desulfurase (NFS1; called IscS in Escherichia coli and
Nfs1 in Saccharomyces cerevisiae), which is required for abstraction of
sulfur from cysteine, leading to alanine (Fig. 5) [66]. In eukaryotes,
two monomers of a small accessory protein, ISD11 (also known as LYR
motif-containing 4, LYRM4), are bound to the NFS1 dimer. The interac-
tion of ISD11 with NFS1 promotes NFS1 stability [67] and causes a
conformational change in the enzyme allowing the bound cysteine sub-
strate and active site cysteine to be brought into close proximity [68]. InFig. 5. Iron sulfur cluster (ISC) biogenesis. A general schematic of ISC biogenesis in themitochon
the cysteine desulfurase, NFS1, which forms a homo-dimer, and removes sulfur from cysteine (C
ISCU, although frataxinmay be involved. Moreover, ferredoxin reductase and ferredoxins 1 and
(S2-), which occurs in ISCs [7]. After ISCs are assembled on the scaffold, the DNAJ-type co-chape
erone. The newly synthesized ISCs are then transferred from ISCU to recipient apo-proteins t
proteins.the presence of ISD11, NFS1 binds the substrate cysteine at the pyridox-
al phosphate-containing active site, and a persulﬁde intermediate is
formed on the active site cysteine. The abstracted sulfur is then trans-
ferred to one of two monomers of the dedicated scaffold protein, ISCU
(called IscU in bacteria, Isu1 or Isu2 in yeast), which bind at either end
of the NFS1/ISD11 core [69], but at a site distal to ISD11 (Fig. 5), with
iron being supplied by an unknown source (perhaps frataxin; reviewed
further below).
ISCU is crucial as it provides a protein-scaffolding, consisting of a
polypeptide backbone structure and cysteine ligands, on which the
nascent ISC can be synthesized [6,46]. In mammals, ISCU is found in
both the mitochondria and cytosol, and may contribute to ISC biogene-
sis in both [70a]. Assembly of the nascent ISCs on ISCU relies on a source
of electrons in order to achieve the appropriate electronic conﬁgura-
tions for the given ISC [7] (Fig. 5). In yeast, the ferredoxin reductase,
Arh1, and ferredoxin, Yah1, may utilize NAD(P)H as an electron donor
[65,70b,70c]. In mammals, the ferredoxin reductase (FDXR) and ferre-
doxins 1 and 2 (FDX1/2) appear to be involved in this activity [70b,c]
(Fig. 5).
Currently, the source of iron necessary for ISC biogenesis is un-
known. In the case of mitochondrial ISC biogenesis, it is likely that
iron is delivered to ISCU by an as yet undetermined chaperone, such
as the mitochondrial protein, frataxin [3,71]. Frataxin is critical for ISC
biogenesis and can bindmultiple iron(II) ions on exposed acidic patches
[3,71,72]. Alternatively, this proteinmay perhaps act as a crucial regula-
tor of ISC formation [7,73], via allosteric regulation of the cysteine
desulfurase activity of NFS1 [74] and/or regulation of ISCU [75]. Another
potential source of iron is the iron-binding complex of glutathione and
glutaredoxin that can tether an ISC [76].
Once synthesized, nascent and labile ISCs must then be transferred
from ISCU to recipient apo-proteins, thereby converting them to their
holo-form (Fig. 5). The complex logistics of this directed transfer of
ISCs to speciﬁc apo-proteins occurs by the concerted action of cluster-
transfer proteins [6]. These proteins work to dissociate the nascent ISC
from the ISCU and ensure accurate and speciﬁc transfer to the correct
apo-proteins. They also assist in the correct assembly and integration
of the ISC at the acceptor site [6,7,65] (see below).
3.3. The core cytosolic ISC biogenesis and delivery (CIA) pathway
In addition to the classical mitochondrial ISC proteins, eukaryotic
cells contain numerous cytosolic and nuclear ISC proteins that aredria of human cells. ISCs are assembled on the ISC assembly enzyme (ISCU). ISCU binds to
ys), providing the sulfur necessary for ISC synthesis. It is not clear how Fe is delivered to the
2 utilize electrons from NADPH to reduce sulfane (S0), which occurs in cysteine, to sulﬁde
roneHSC20 binds to ISCU and, in turn, this complex binds an ATP-dependent HSPA9 chap-
o convert them to their holo-form with the help of various chaperones and/or accessory
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thesis, and DNA repair. As such, the synthesis of ISCs for incorporation
into the respective proteins in the cytosol and nucleus are vital for cellu-
lar viability. The major process involved in the synthesis of these extra-
mitochondrial ISCs occurs in two major steps of a highly conserved
eukaryotic pathway, known as the cytosolic ISC protein assembly
(CIA) pathway, that involves nine known proteins (for a recent excel-
lent review, see: [77a]). The below overview will describe the major
components of the budding yeast pathway, but the mechanisms and
proteins involved are highly conserved in mammals [77b]. In the ﬁrst
step of the CIA pathway in yeast, a [4Fe-4S] cluster is assembled on a
scaffoldinghetero-tetrameric complex composedof the P-loopNTPases,
Nbp35 and Cfd1 (NUBP1 and NUBP2 in humans, respectively), which
requires a currently unknown source of sulfur (designated “X-S”) that
appears to be exported from mitochondria by Atm1 (ABCB7 in
humans). Additionally, an intermembrane space sulfhydryl oxidase,
Erv1 (GFER in humans), is thought to be involved in disulﬁde formation
and the facilitation of export of this unknown intermediate to the cyto-
sol [77c,d]. In similarity to themitochondrial ISC system, in order to gen-
erate the appropriate electronic conﬁguration of the cluster on the
Nbp35-Cfd1 complex, a source of reducing equivalents is required,
which utilizes an NADPH-dependent electron transfer chain involving
the FAD- and FMN-containing ﬂavoprotein, Tah18 (NDOR1 in humans),Fig. 6. Possible roles for mitochondrial frataxin. There have been four major roles hypothesized
storage; (B) iron chaperone; (C) allosteric regulator; and (D) metabolic switch. Each of these ro
frataxin, at least in yeast, may perform an iron-storage function within the mitochondrial mat
matrix and then delivering it to either the ISC assembly complex of the ISC biosynthetic path
that frataxinmay play the role of an allosteric regulator of desulfurase activity of the NFS1-ISD1
desulfuration. (D) Frataxinmay function as a type of ‘metabolic switch’ that allows themitochon
anism behind this ‘switching’ may be the relative afﬁnities of frataxin for ferrochelatase (i
ferrochelatase over ISCU at relatively lower frataxin levels.
Modiﬁed from (Richardson et al.) [3].that transfers electrons to the ISC of Dre2 (CIAPIN1 in humans)
[77a,77e,f].
In the second step, the nascent ISCs are transferred from the Nbp35-
Cfd1 scaffolding complex to speciﬁc apo-proteins by the concerted
actions of the iron-hydrogenase-like protein, Nar1 (IOP1 in humans),
and the CIA targeting complex, which is a hetero-trimeric complex
consisting of Cia1 (CIA1/CIAO1 in humans), Cia2 (CIA2A/FAM96A or
CIA2B/FAM96B in humans, which target different sets of apo-acceptors)
and Mms19 (MMS19 in humans) (reviewed in depth in [77a]). The lat-
ter three proteins are crucial for interacting with target apo-proteins
and ensuring speciﬁc and efﬁcient transfer of ISCs [78a]. The
glutaredoxins, Grx3 and Grx4, which are capable of binding a GSH-
coordinated, bridging [2Fe-2S] cluster, are also known to be involved
in the CIA pathway, but at an as-yet-unknown step [77a,78a].
In the human CIA pathway, there are several crucial differences that
are worth noting. First, while the components and biochemical mecha-
nisms of the human CIA pathway are similar to those in yeast, there is
a crucial difference in that, human cells express two isoforms of CIA2
(i.e., CIA2A and CIA2B), both of which bind to CIA1. Importantly, CIA2B
is the functional ortholog of Cia2 in yeast, and is involved in canonical
ISC assembly in cytosolic and nuclear ISC proteins. However, CIA2A is
known to be speciﬁcally involved in the ISC assembly for IRP1
[78b], which is a crucial regulator of cellular iron homeostasis infor the function of frataxin in mitochondrial iron metabolism in eukaryotic cells: (A) iron
les may be complementary and not exclusive of each other. (A) It has been proposed that
rix. (B) Frataxin may function as an iron chaperone by binding iron in the mitochondrial
way, or ferrochelatase of the heme biosynthetic pathway. (C) Recent evidence suggests
1-ISCU complex such that by binding to the complex, frataxin increases the rate of cysteine
drion to favor hemeor ISC/heme syntheses, depending on frataxin levels. A possiblemech-
.e., 17 nM) vs ISCU (i.e., 480 nM). This may result in preferential binding of frataxin to
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view, see [77a]). Intriguingly, although IRP2 does not possess an
ISC, IRP2 is still bound, and stabilized, by CIA2A [78b]. This is impor-
tant in considering the possible mechanisms by which cellular ISC
biogenesis may intersect with the classical regulatory pathways for
the IRPs described above.4. Further insights into mitochondrial ISC biogenesis and delivery:
some key players and mechanisms
While there remain numerous molecular and biochemical details of
themitochondrial ISC biogenesis pathway that have not been fully char-
acterized, several discoveries have revealed important insights into the
process. Only an overview of some these discoveries and mechanistic
insights is detailed below, as this topic has been recently reviewed [78a].4.1. Frataxin and ISC biogenesis
Frataxin is essential for cellular iron homeostasis [79], and it is in-
volved in regulating systemic iron homeostasis by an as-yet-unknown
mechanism [3,62,79,80]. In addition, evidence supports its role as an es-
sential factor in ISC biogenesis [79]. Crucially, frataxin-deﬁciency causes
the rare, but severe neuro- and cardio-degenerative disease, FRDA,
which is due to a GAA-repeat expansion in intron 1 of FRDA gene that
encodes for frataxin [81]. Frataxin is a vital protein that is highly
expressed in tissues rich in mitochondria e.g., heart and neurons [82],
with total deletion being embryonically lethal [83].
Most suggested functions for frataxin, a mitochondrial matrix pro-
tein [79,81], relate to iron-binding and maintenance of mitochondrial
iron metabolism (Fig. 6). These proposed functions include mitochon-
drial iron storage (for a recent review see [79]) (Fig. 6A), which is con-
sidered an unlikely role in mammalian cells, because of the presence of
FTMT, which plays an iron storage role in themitochondria of some cell
types; as well as the regulation of ISC biogenesis (Fig. 6B, C and D) and
heme synthesis (Fig. 6B and D) [84]. However, most evidence suggests
frataxin is involved in the maintenance of mitochondrial ISC biogenesis
and/or heme synthesis [79] and/or allosteric activation of the NFS1-
ISD11-ISCU complex (see below).
Many insights regarding frataxin function have come from studies of
frataxin orthologs in yeast (i.e., Yfh1) and bacteria (i.e., CyaY) [85]. A
consensus exists that the functions of frataxin share a requirement for
iron-binding [85]. The major proposed roles for frataxin in ISC biogene-
sis are discussed below.4.2. Frataxin as an iron chaperone
It has long been suspected that frataxin is an iron chaperone for ISC
biogenesis and/or heme biosynthesis (Fig. 6B). Frataxin has been
observed to interact with, and presumably donate iron to, iron-
dependent proteins involved in ISC biogenesis and/or heme synthesis
[86,87]. For example, yeast frataxin, Yfh1, can interact with the core
ISC assembly complex comprising the scaffolding protein, Isu, and the
cysteine desulfurase, Nfs1, which is enhanced by iron(II) [86,88].
In a similarmanner, human frataxin also interacts with ferrochelatase
for heme synthesis [87,89]. Importantly, the interaction of frataxin
with either ISCU or ferrochelatase appears to increase the rate of ISC
synthesis [86], or the ferrochelatase-catalyzed insertion of iron(II) into
PPIX [87], respectively. These observations suggest frataxin donates iron
to ISCU and/or ferrochelatase.
Intriguingly, accumulating data suggests the role of frataxin in ISC
biogenesis may be more complex than just iron-donation. As discussed
further below, the interaction of frataxin with the core ISC biogenesis
apparatus, and perhaps ferrochelatase during heme synthesis, may
serve to kinetically regulate key reactions.4.3. Frataxin as an iron-sensing, allosteric regulator
A 2009 study suggested that the bacterial frataxin ortholog, CyaY,
may act as an “iron-sensor” and kinetic regulator that negatively
regulates ISC biosynthesis under conditions of high iron and low ISC
apo-acceptor availabilities [90] (Fig. 6C). This is dependent on the bind-
ing of frataxin to IscS (the bacterial equivalent of NFS1) [73,90,91].
Although CyaY does not inhibit the desulfurase activity of IscS, it
slows down the rate of ISC formation in an iron-dependent manner
via a CyaY-dependent increase in the afﬁnity of IscS for the scaffold pro-
tein, IscU [91,92]. This increase in afﬁnity between the two proteinsmay
inhibit the release of the scaffold protein from the cysteine desulfurase
during the delivery of the nascent ISC. Thus, in prokaryotic systems,
CyaY appears to regulate ISC biogenesis by acting as an iron-dependent
inhibitor of the IscS-IscU core complex.
Similar studies in eukaryotic systems indicate that, rather than act-
ing as an inhibitor, frataxin acts as an activator of ISC biogenesis [73,
93,94a]. Indeed, in 2010, Tsai and Barondeau demonstrated that
human frataxin acts as an iron-dependent allosteric switch that acti-
vates the core ISC biogenesismachinery bymarkedly increasing the cys-
teine desulfurase KM and catalytic efﬁciency (kcat/KM) [94a]. Moreover, a
recent study by Pandey and colleagues indicates that yeast frataxin (i.e.,
Yfh1) directly stimulates the cysteine desulfurase of Nfs1 activity by
binding to the enzyme and exposing substrate-binding sites [74]. In-
triguingly, amutant formof the scaffold protein, Isu1,which can operate
independently of Yfh1, causes a similar increase Nfs1 activity by the
samemechanism [74]. Bridwell-Rabb and colleagues [94b] have provid-
ed evidence supporting this allosteric activation model and have pro-
posed that frataxin accelerates persulﬁde formation on NFS1 and
favors a helix-to-coil interconversion on ISCU2 that helps drive the
transfer of sulfur from the NFS1-ISD11 complex to ISCU2. Moreover, a
very recent study by Parent and colleagues [94c] has indicated that
mammalian frataxin directly enhances the rate of two similar reactions,
including NFS1 persulﬁde transfer to thiols on ISCU and small thiols
such as L-cysteine and GSH. Thus, eukaryotic frataxin appears to be an
allosteric activator of the persulﬁde-forming activity of the NFS1-
ISD11-ISCU complex (Fig. 5).
Interestingly, the apparent opposing effect in the regulation of
ISC biogenesis by the prokaryotic and eukaryotic frataxin orthologs
(i.e., prokaryotic frataxin appears to be an inhibitor, while eukaryotic
appears to be an activator) seems to be dependent on the identity of
the cysteine desulfurase, rather than the frataxin ortholog [95].
4.4. Is frataxin a “metabolic switch” between ISC biogenesis and heme
synthesis?
An extension of the allosteric regulator model of frataxin in ISC
biogenesis may also be applicable to frataxin's ability to regulate heme
biosynthesis and act as ametabolic switch (Fig. 6D). As there is a decline
in frataxin levels during erythroid differentiation, and since frataxin ex-
pression is markedly decreased during Friend cell hemoglobinization
[96], it has been proposed that frataxin is down-regulated during ery-
throid differentiation to allow for higher rates of heme synthesis, poten-
tially at the expense of decreased levels of ISC synthesis [3,79,84,96].
This hypothesis is supported by the observation that the immediate
precursor for heme synthesis, PPIX, down-regulates frataxin expres-
sion [96]. Hence, increased PPIX levels, which indicate a requirement
for heme synthesis, lead to decreased frataxin expression and a diver-
sion of iron from other mitochondrial pathways (i.e., ISC synthesis
and/or iron storage) to heme biogenesis [96].
This latter hypothesis is supported by the observation that an in-
crease in frataxin levels relative to ferrochelatase (i.e., above a molar
ratio of 1:1 frataxin:ferrochelatase dimer) results in decreased rates of
heme synthesis in vitro [87]. It has also been observed that iron-bound
human frataxin has a higher putative binding afﬁnity for ferrochelatase
(17 nM) than Isu (480 nM) [87]. These observations provide a basic
Fig. 7. Iron sulfur cluster (ISC) delivery. Addition of ISCs to succinate dehydrogenase subunit B, SDHB. ISCs assembled on the ISCU are transferred to the ISC protein, SDHB, by a chaperone-
co-chaperone system. In the SDHB protein sequence, two LYR motifs and the KKX7KK consensus sequence bind to HSC20 to engage the ISCU-HSC20-HSPA9-complex and aid the incor-
poration of three ISCs.Moreover, the accessory protein, SDHAF1, binds bothHSC20 at a LYRmotif and SDHB at a non-LYR binding site, facilitating the delivery of the ISC from ISCU to SDHB.
Upon acquisition of three ISC centers, SDHB forms one of the four subunits in complex II (SDH).
Modiﬁed from (Lane et al.) [130].
1138 D.J.R. Lane et al. / Biochimica et Biophysica Acta 1853 (2015) 1130–1144mechanism that supports the hypothesis that frataxin expression levels
may allowmetabolic switch between the ISC biogenesis and heme syn-
thesis pathways, depending on expression levels relative to those of Isu
and ferrochelatase [87,96]. That is, in analogy to the allosteric regulation
of the Nfs1-Isd11-Isu1 complex, frataxin may also exert kinetic regula-
tion of heme synthesis by binding to and inhibiting ferrochelatase
at frataxin/ferrochelatase ratios above parity, a scenario in which
ferrochelatase is progressively inhibited by frataxin [87]. Similarly, a de-
crease in the frataxin/ferrochelatase ratio below parity may also be in-
hibitory to heme synthesis, as frataxin-deﬁcient murine heart tissue
shows increased PPIX levels and decreased heme production [62,97].
Importantly, a decrease in the frataxin/ferrochelatase ratio, as in the
case of frataxin-deﬁciency, affects both the transcriptome and proteome
of enzymes in the heme synthetic pathway [62,97].
Taken together, the emerging view of frataxin function inmitochon-
drial ironmetabolism is one of an allostericmodulator and/ormetabolic
switch between two key pathways: ISC biogenesis and heme synthesis
(Fig. 6D). Whether frataxin is the elusive source of iron for ISC biogene-
sis, or whether iron-binding to frataxin is merely a means of regulating
its allosteric activity in an iron-dependent manner, is yet to be deter-
mined. Furthermore, some studies indicate that frataxin may also have
a role in facilitating ISC delivery (see below).5. HSP70, HSC20 and the logistics of mitochondrial ISC delivery
One key unresolved question in the ISC biogenesis and delivery ﬁeld
has been determining how speciﬁc ISCs are directed to cognate target
proteins. In fact, although the delivery pathway for nascent ISCs is still
relatively uncharacterized, as with the CIA pathway (see above), key
players and their mechanisms of action are emerging. We here provide
only an overview of some these discoveries and mechanistic insights
with respect to mitochondrial ISC biogenesis, as this topic has been re-
cently reviewed in depth [78a].
The targeted delivery of nascent ISCs to speciﬁc apo-acceptors in-
volves a dedicated HSP70-chaperone–HSC20-co-chaperone pair of pro-
teins that transfers the ISCs from the primary scaffold (referred to
herein as “ISCU”) to speciﬁc recipient proteins [7] (Fig. 7). In bacteria
and yeast, holo-ISCU (i.e., harboring a nascent ISC) must dissociate
from the cysteine desulfurase (NFS1) and bind to an HSC20 J-protein
(HscB in bacteria, Jac1 in yeast) through hydrophobic contacts [7,98].
ISCU must also bind to an HSP70 chaperone (HscA in bacteria, Ssq1 in
yeast, possibly HSPA9 in mammals) via a conserved LPPVK-motif inISCU [98]. Binding of the J-domain of the HSC20 protein (speciﬁcally a
His-Pro-Asp motif) to HSP70 leads to activation of the latter's intrinsic
ATPase activity, which hydrolyzes ATP and causes a conformational
change in the ISCU-binding domain of HSP70 [98]. This is thought to
facilitate extrusion of the LPPVK-motif of ISCU, promoting a conforma-
tional change in ISCU that may allow for transfer of the ISC to recipient
apo-proteins or to secondary scaffolds [98] (Fig. 7).
5.1. The HSP70 protein
Unlike bacterial and yeast systems, most eukaryotic mitochondria
do not appear to have a HSP70 member that is dedicated to ISC assem-
bly and transfer [45]. Although it is yet to be conclusively demonstrated,
the available evidence suggests that a multi-functional mitochondrial
HSP70, namely HSPA9/mortalin/mtHSP70/GRP75/PBP74, is capable of
“moon-lighting” in this role [99–101]. Interestingly, HSPA9/mortalin is
involved in many cellular processes including facilitation of protein-
folding and import, intracellular trafﬁcking, the cellular stress response,
hematopoiesis, control of cell proliferation and tumor progression [102].
Further genetic studies are needed to demonstrate the role of HSPA9/
mortalin in vertebrate ISC biogenesis and delivery.
5.2. The HSC20 protein
The protein now known as HSC20 was originally predicted to be in-
volved in ISC biogenesis due to its similar phylogenetic distribution to
frataxin and its high levels of expression in mitochondria [103]. More
recently, several studies have implicated this J-protein type III co-
chaperone in ISC synthesis [100,101,104] (Fig. 7). Indeed, human
HSC20 can be substituted for its yeast counterpart, Jac1, and has been
shown to directly interact with ISCU and HSPA9/mortalin [104]. RNAi-
depletion of HSC20 resulted in a deﬁcit of mitochondrial and cytosolic
ISC proteins [100,104]. Moreover, HSC20 possesses a cysteine-rich N-
terminal domain, which differs from its counterparts in bacteria and
yeast, which may be important in protecting nascent ISCs from oxida-
tive insults [104]. While HSC20 is located predominantly in mitochon-
dria, some of the protein is also found in the cytosol, where it may
contribute to cytosolic ISC-biogenesis and delivery [104].
Intriguingly, frataxin has been found to interact with HSC20 in an
iron-dependent manner, and HSC20 levels are regulated by frataxin
levels [100]. If frataxin is involved in regulating the kinetics of the cyste-
inedesulfurase complex,whydoes theprotein also interactwithHSC20,
Fig. 8. Somemajor alterations in cellular ironmetabolism in the heart of frataxin-deﬁcient
mice. Frataxin deﬁciency leads to an increase in mitochondrial iron-uptake and a conse-
quent cytosolic iron deﬁciency, which is facilitated by (i) TfR1 upregulation, increased
Tf-dependent iron uptake; (ii) FPN1 down-regulation, preventing iron release; and
(iii) ferritin down-regulation, preventing cytosolic iron storage. These changes presum-
ably result from a decrease in cytosolic iron leading to an increase in IRP2 levels. Iron is
taken up avidly by the mitochondrion, in part, via an increase in MFRN2, and there is a
down-regulation of the three major pathways of mitochondrial iron utilization, namely:
ISC biogenesis, heme synthesis, and mitochondrial iron storage (FTMT). The decreased
iron utilization in these pathways reduces iron export from the mitochondrion as heme
and ISCs,which is coupledwith an increase inmitochondrial non-ferritin and redox-active
iron deposits as inorganic crystallites. The latter lead to an increase in reactive oxygen spe-
cies (ROS) production, which is potentiated by a decrease in NRF2-regulated anti-oxidant
enzymes.
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though many possibilities exist, the interaction of frataxin with HSC20
may indicate that frataxin allows ﬁne-tuning of ISC biosynthetic rates,
through protein–protein interactions with key players, in response to
ISC apo-acceptor availability. This scenario would be reminiscent
of the proposed ability of the bacterial frataxin ortholog, CyaY, to
down-regulate ISC biogenesis in response to low apo-acceptor availabil-
ity [90].
5.3. The role of LYR motifs in HSC20 client discrimination
Type III J-proteins, such as HSC20, do not typically act alone as mo-
lecular chaperones, and are known to interact selectively with a small
subset or even a single substrate [105]. Until very recently, the answer
to the question of how speciﬁc ISCs are directed to target proteins was
unknown.
Interestingly, a recent study fromRouault's group has revealed basic,
but crucial, insights into the molecular logistics of HSC20-mediated cli-
ent discrimination in the transfer of ISCs to discrete subsets of recipient
proteins [101]. Maio and colleagues have shown that HSC20 guides na-
scent ISCs to their cognate apo-acceptors based, in part, on a highly con-
served “leucine–tyrosine–arginine” (LYR) motif in target proteins [101]
(Fig. 7). These authors discovered that HSC20 binds the succinate dehy-
drogenase subunit B (SDHB; the ISC-containing subunit of respiratory
chain complex II), and demonstrated that both HSC20 and HSPA9/
mortalin were required for complex II assembly and activity [101].
When these authors examined the SDHB sequence more closely, they
identiﬁed two LYR motifs [101] that are highly conserved within
eukaryotes and prokaryotes [106].
The LYR motif (LYRM) family of mitochondrial proteins consists of
proteins of diverse functions that typically carry this tri-peptide motif
in the N-terminal region [106]. These proteins appear to function as
adaptor-like or accessory factors in the control ofmitochondrial homeo-
stasis, particularly ISC biogenesis and delivery and fatty acid synthesis
[106]. Maio and colleagues were able to determine that the LYRMs in
SDHB are responsible for binding the C-terminal domain of HSC20 and
thereby engage the ISC transfer apparatus (Fig. 7). A third binding site
for HSC20 was also discovered in the SDHB sequence. This binding site
comprises a KKX7KK sequence and is located at the C-terminal end of
SDHB (Fig. 7). While the functional signiﬁcance of this HSC20-binding
site is unclear, similar sequences are present in the C-terminal ends of
two other proteins (i.e., glutaredoxin 5 and SUCLG2) that were further
identiﬁed as HSC20-binding partners [101].
An additional signiﬁcant ﬁnding in the Maio et al. study was that
succinate dehydrogenase assembly factor 1 (SDHAF1), which partici-
pates in complex II assembly, binds to SDHB through a non-LYR site
[101]. This is signiﬁcant, as the authors observed that HSC20 bound to
SDHAF1, probably through the LYR site in SDHAF1, suggesting that
SDHAF1 may initially dock with SDHB, which may allow subsequent
HSC20-binding to SDHB and/or perhaps other ISC transfer complexes
that are bound at the LYR binding sites on SDHB (Fig. 7). These seminal
data indicate that the LYRM may represent a marker that allows for
HSC20-dependent client discrimination in the targeted delivery of ISCs
to recipient proteins.
The ﬁnding that HSC20 is guided, at least in part, by LYRMs in target
proteins is important as other LYRMproteins are known to play a role in
ISC biogenesis and delivery from complexes I-III [106]. These include
ISD11, the obligate NFS1-binding partner [107], SDHAF1 and SDHAF3,
the latter twoofwhichwere recently shown to be involved inmediating
the maturation of the SDHB [108]. Additionally, Winge's group has also
shown that the LYRM protein, Mzm1, functions in the insertion and/or
stabilization of the ISC-containing subunit of complex III [109a]. Taken
together, these recent ﬁndings suggest that these proteins are guided
by their LYRMs for ISC biogenesis and the targeted delivery of ISCs to
proteins. As the human genome encodes at least 11 LYRM proteins
[106], it will be crucial for further studies to consider the possibleinteraction between HSC20 and these proteins in ISC biogenesis and
delivery.5.4. Other proteins associated with mitochondrial ISC delivery
In addition to the proteins reviewed above, othermitochondrial pro-
teins have been found to play a role in delivery of ISCs to speciﬁc apo-
proteins. These include, human NFU1, which can assemble a [4Fe-4S]
cluster per two NFU1 monomers and appears to be a late acting factor
that is speciﬁcally required for the maturation of lipoic acid synthase,
with mutations in the NFU1 gene being associated with a disruption of
lipoic acid metabolism [109b]. Another group of proteins, which were
initially suspected to act as alternative scaffolds in mitochondrial ISC
biogenesis, but have recently been shown to be involved in thematura-
tion of a subset of ISC-containing apoproteins, are the A-type proteins.
In mammals, ISCA1, ISCA2 and IBA57 appear to be additional speciﬁc
late acting factors in themitochondrial ISC assembly pathway that facil-
itate the maturation of [4Fe-4S] clusters on target apoproteins [109c].
For further information, as well as the roles of glutaredoxins and BOLA
proteins, see [78a] and [109d] for excellent recent reviews.
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loading and cytosolic iron-depletion?
One of the most common phenotypes of defective ISC biogenesis is
the development of mitochondrial iron-loading, with subsequent mito-
chondrial damage resulting, to some degree, from oxidative stress [3,7,
47,84]. Indeed, disruptions to mitochondrial ISC biogenesis cause
cytosolic iron-depletion and/or mitochondrial iron-loading [3,7,47,84].
For example, mitochondrial iron-loading occurs in: (i) erythroid
progenitors of a sideroblastic anemia patient resulting from a GLRX5-
deﬁciency [110]; (ii) skeletal myocytes of individuals with ISCU myop-
athy [111]; Abcb10-knockoutmice, which causes anemia due to ineffec-
tive erythropoiesis in erythroid progenitors [56] (iii) cardiomyocytes
and some neurons in FRDA and FRDA models [62,80,84,112,113].
6.1. Lessons learnt from frataxin deﬁciency
In the case of frataxin deﬁciency, the iron accumulation in affected
cells occurs as redox-active, biomineral iron aggregates that are bio-
chemically distinct from holo-ferritin molecules [80]. Mitochondrial
iron accumulation has been detected in the heart, liver, and spleen,
but not in the dorsal root ganglion, spinal cord, cerebellum, peripheral
nerves, skeletal muscle, or pancreas of FRDA patients [112]. Interestingly,
in theMCK transgenic mice harboring frataxin deﬁciency in the heart, di-
minished ISC enzyme activity was observed prior to the onset ofFig. 9. X-linked sideroblastic anemia with cerebellar ataxia (XLSA/A) and schematic of a po
sideroblastic anemiawith cerebellar ataxia (XLSA/A). XLSA/A is caused bymutation in themitoc
ISCs. This mutation leads to elevated PPIX levels and decreased Fech activity, possibly due to t
mitochondrial iron. (B) Recent studies have suggested the existence of an interaction betwee
This interaction involves the formation of a higher-order multimeric complex that enhances t
The formation of this multimeric complex is likely to facilitate the efﬁcient mobilization of me
cytosol; OM, outermitochondrial membrane; IMS, inter-mitochondrial membrane space; IM, in
cluster; CPO, coproporphyrinogen III oxidase; PPO, protoporphyrinogen III oxidase.
Modiﬁed from (Huang et al.) [47].mitochondrial iron accumulation [114], suggesting that, in frataxin deﬁ-
ciency, dysregulation in ISC biogenesis/metabolism precedes the precipi-
tation of microcrystalline iron aggregates in the mitochondria [80].
Analysis of gene and protein expression in the MCK frataxin knock-
out mice identiﬁed a mechanism of iron redistribution characterized by
anupregulation of genes involved in cellular andmitochondrial iron up-
take (i.e., TfR1 and Mfrn2, respectively), and down-regulation of genes
encoding proteins involved in cytosolic iron storage (i.e., ferritin-H and
-L chains), cellular iron efﬂux (i.e., Fpn1), mitochondrial heme synthesis
(i.e., δ-aminolevulinate dehydratase, uroporphyrinogen III synthase and
ferrochelatase), and ISC biogenesis (Iscu 1/2 and Nfs1) [62]. In addition,
it was shown in vivo in MCK frataxin-knockout mice that 59Fe uptake
from radiolabeled holo-transferrin was markedly increased in frataxin
deﬁcient hearts relative to wild-type mice, and further, that redistribu-
tion of 59Fe from the cytosol to the mitochondria occurred [113]. These
data suggest increased iron uptake occurred via themarked elevation in
TfR1, and that the increased mitochondrial iron accumulation results
from increased mitochondrial iron uptake [62,113].
In fact, in the MCK frataxin knockout heart, mitochondrial iron-
loading resulted from up-regulated iron uptake, decreased cytosolic
iron storage and increased mitochondrial iron accumulation, coupled
with defective iron incorporation into hemeand ISCs [62,113]. In the ab-
sence of frataxin, the marked iron uptake into the frataxin deﬁcient mi-
tochondria is not effectively incorporated into heme or ISCs, nor is it
effectively incorporated into FTMT, as its expression is reduced [62,ssible mitochondrial iron-transport complex in the developing erythron. (A) X-linked
hondrial transporter Abcb7,which has been suggested to be the exporter ofmitochondrial
he requirement of Abcb7 for Fech's activity, and ultimately results in the accumulation of
n the mitochondrial transporters and the terminal enzymes involved in heme synthesis.
he efﬁciency of the activities of each of the component proteins, such as Mfrn1 and Fech.
tabolites and intermediates for the synthesis of heme during erythroid differentiation. C,
ner mitochondrial membrane; M,mitochondrial matrix; H, heme; P, PPIX; ISC, iron–sulfur
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mitochondrion leads to toxic mitochondrial iron-loading that promotes
oxidative stress (Fig. 8).
Importantly, the oxidative stress in frataxin deﬁcient cells is potenti-
ated by a decrease in the antioxidant nuclear factor-erythroid 2-related
factor 2 (NRF2) signaling pathway [115–117] (Fig. 8). This pathway
drives a major antioxidant cellular response to oxidative stress by up-
regulating the expression of genes possessing a cis-acting anti-oxidant
response element (ARE) [118,119], leading to increased levels of major
antioxidant enzymes, such as the superoxide dismutases, catalase, glu-
tathione reductase, glutathione-S-transferase, the glutamate-cysteine
ligase catalytic subunit, and NADH quinone oxidoreductase [118,120].
The down-regulation of the NRF2 signaling pathway by frataxin deple-
tion appears to be due to a decrease in NRF2 expression and/or a
decrease in NRF2 translocation to the nucleus [115–117], the latter of
which is required for increased transcription of ARE-containing genes
[118,119]. The molecular mechanism(s) leading to a down-regulation
of NRF2 may be an important aspect of the FRDA pathogenesis that
warrants further exploration.6.2. Hypotheses for regulation of cellular iron metabolism by ISC biogenesis
How does ISC biogenesis regulate cellular iron metabolism? While it
was initially suggested that iron could only exit the mitochondrion fol-
lowing incorporation into an ISC [121], this view was later reformulated
to suggest ABCB7, a mitochondrial half-transporter located in the IMM,
had a role in the mitochondrial export of a sulfur-containing moiety re-
quired for cytosolic ISC biogenesis [6]. Whether iron is also transported
by ABCB7 is unknown and the identity of the ABCB7 export substrate re-
mains unclear [6]. Importantly, ABCB7 appears to be required for cytosolic
ISC biogenesis. As might be expected, mitochondrial iron-loading occurs
in X-linked sideroblastic anemia with ataxia, which is caused by
mutations in ABCB7 (Fig. 9A) [122]. Indeed, studies in developing
erythrons suggest that mitochondrial iron utilization for ISC and heme
synthesis is a tightly coupled process involving a metabolon of physically-
interacting mitochondrial membrane transporters under conditions of
an increased requirement for mitochondrial iron [123–126] (Fig. 9B).
One hypothesis for ISC biogenesis-mediated control over cellular
iron metabolism relates to IRP1. Cellular iron metabolism is controlled
by IRP1 and 2, and under normal in vivo conditions, IRP2 is the major
contributor to iron-dependent regulation of the IRP–IRE system [127].
However, there is typically a large pool of IRP1 in the ISC-containing
aconitase form [38,128]. A deﬁcit in ISC biogenesis in the mitochondria
and/or cytosol would be expected to lead to a decrease in the ISC-
containing form of IRP1 and a corresponding increase in the IRP1-IRE-
binding form, which would lead to increased TfR1 and decreased
ferritin. It is known that the depletion of numerous components of the
ISC biogenesis pathway leads to activation of the IRE-binding activity
of IRP1, leading to increased TfR1 and decreased ferritin [see [45]]. For
example, suppression of ISCU by RNAi inactivates mitochondrial and
cytosolic aconitases and leads to inappropriate upregulation of IRP1-
IRE-binding activity, which leads to disrupted iron homeostasis [70a].
In some model systems, frataxin deﬁciency does lead to IRP1-
activation [129]. Indeed, a very recent study suggests that frataxin deﬁ-
ciency in mice leads to mitochondrial iron overload through a combina-
tion of increased Irp1 activation, resulting from defective ISC biogenesis,
and heme deﬁciency-dependent upregulation of Mfrn2 [131]. However,
there is no change in the IRE-binding activity of IRP1 in the heart of
MCK frataxin knockout mice relative to their wild-type counterparts,
which was fully activated from 4 weeks-old [113]. Nevertheless, there is
a signiﬁcant increase in IRP2-IRE-binding activity in the frataxin knockout
mice [113]. Moreover, RNAi-mediated depletion of HSC20 resulted in up-
regulation of TfR1 and IRP2, suggesting a deﬁcit in the J-protein co-
chaperone also leads to a state of cytosolic iron deﬁciency andmitochon-
drial iron-loading [100]. This suggests IRP2-activation can have primacyover IRP1-activation in termsof responding to iron levels in some settings,
although the mechanism is unclear.
7. Conclusions and perspectives
The list of diseases with a defect in ISC biogenesis and delivery is
growing. In this review, we have discussed the ﬁeld of iron- and ISC-
biogenesis from the initial uptake of iron by the cell to its utilization in
ISC biogenesis. We have discussed the major players involved in their
biogenesis and delivery to target proteins, as well as highlighting new
players and mechanisms that have provided insight into the processes
involved and how these connected processes are regulated. We have
further suggested ways in which mitochondrial ISC biogenesis may be
linked with cellular iron processing; a hypothesis clariﬁed by analysis
of diseases of ISC assembly (e.g., FRDA). Increased knowledge of mito-
chondrial “ins-and-outs” of iron-cofactor processing pathways, and
their ability to communicate with the other compartments (e.g., the
cytosol), will help shape the investigation of iron metabolism in health
and disease.
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